Sigmas Group

Activity from announced rounds

Activity in this selectionOct 24, 2026 · Biotech · Jan 1, 2026
Rounds participated in
2
Confirmed lead rounds
0
1 roles undisclosed
New companies
2
First participation on record · 0 follow-on
Funding in participating rounds
$112M
2 disclosed · full round size, not this investor’s share

By stage

Series C+1
Undisclosed1

By primary sector

Biotech2

By country

United States2

Rounds

2 in this selection
BigHat Biosciences

An AI and synthetic-biology platform that designs and engineers antibody therapeutics.

$75MSeries C
Participant
Centivax

Develops vaccines and therapies for universal protection against diverse targets

$37MUndisclosed
Role not disclosed